Version history

{
  "session_id": "sess_SDA-2026-04-10-gap-debate-20260410-100357-76f5b31e",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "mini-max",
  "action": "propose",
  "content": "\n\n# Mechanistic Hypotheses: Selective Targeting of Pathological Tau\n\nBased on the research gap regarding identification of disease-specific tau modifications enabling selective therapeutic targeting.\n\n---\n\n## Hypothesis 1: Lysine Acetylation at K280/K274 as a Selective Therapeutic Window\n\n**Description:** Acetylation at K280 (human tau numbering) occurs specifically in pathological tau and disrupts microtubule binding while promoting aggregation. This modification is catalyzed by p300/CBP and removed by SIRT1; disease-state imbalance favors acetylation. Unlike global phosphorylation, K280 acetylation creates a unique \"docking station\" for further pathological modifications and can be reversibly targeted.\n\n**Target:** K280 acetylated tau (p300/CBP as upstream writer, SIRT1 as eraser)\n\n**Confidence:** 0.78\n\n---\n\n## Hypothesis 2: Caspase-3 Cleavage at D421 Generates Pathology-Permeable Tau Fragments\n\n**Description:** Truncation at Asp421 by caspase-3 occurs in diseased neurons and creates a C-terminal fragment that rapidly aggregates and exhibits cell-to-cell transmission properties. This cleavage exposes the VQIII-repeat domain, enhancing β-sheet formation. Selective inhibition of this cleavage site (while sparing normal proteolytic processing) could block formation of the most infectious tau species.\n\n**Target:** Caspase-3; tau D421 cleavage site\n\n**Confidence:** 0.82\n\n---\n\n## Hypothesis 3: Loss of O-GlcNAcylation at S400/T403 Triggers Pathological Phosphorylation Cascade\n\n**Description:** O-GlcNAcylation at S400 and T403 normally protects these sites from phosphorylation. In neurodegeneration, decreased glucose metabolism reduces O-GlcNAc transferase (OGT) activity, creating a permissive environment for hyperphosphorylation at adjacent sites (S396, S404). This \"glyco-phospho switch\" represents an early pathological event that could be restored pharmacologically via OGT activation or direct O-GlcNAc mimetics.\n\n**Target:** OGT; tau S400/T403 O-GlcNAcylation\n\n**Confidence:** 0.71\n\n---\n\n## Hypothesis 4: Conformation-Selective N-terminal Truncation Generates Soluble Pathogenic Tau\n\n**Description:** Calpain-mediated cleavage between residues 26-230 creates N-truncated tau species that maintain solubility but exhibit increased interaction with neuronal membranes and enhanced exosomal packaging. These fragments act as \"Trojan horses\" for tau propagation and are detectable in cerebrospinal fluid, making them candidate biomarkers. Targeting this cleavage event could interrupt spreading without affecting functional microtubule-binding tau.\n\n**Target:** Calpain; tau N-terminal cleavage products\n\n**Confidence:** 0.69\n\n---\n\n## Hypothesis 5: Pathological Tau Acquisition of Prion-Like Conformational Epitopes\n\n**Description:** Specific PTMs (phosphorylation at S262, acetylation at K280) induce allosteric changes that create novel conformational epitopes recognized by antibodies like TOMA and TNT2. These epitopes are absent in normal tau and span the 4R-repeat domain. Therapeutic antibodies or small molecules stabilizing the \"closed\" normal conformation could prevent the pathological structural transition without affecting normal tau function.\n\n**Target:** Pathological tau conformational states; tau repeat domain\n\n**Confidence:** 0.75\n\n---\n\n## Hypothesis 6: Mitochondrial Targeting Sequence Modification in Disease-State Tau\n\n**Description:** Under pathological conditions, tau undergoes modifications (phosphorylation at Y18, oxidation at C291/C322) that enable aberrant translocation to mitochondria. Mitochondrial tau disrupts protein import, impairs complex I function, and increases ROS production. This modification creates a disease-specific compartment that could be targeted to restore mitochondrial homeostasis without affecting cytoskeletal tau.\n\n**Target:** Mitochondrial tau; tau Y18 phosphorylation\n\n**Confidence:** 0.64\n\n---\n\n## Hypothesis 7: Proline-Directed Phosphorylation at T231/S235 as Nucleation Event\n\n**Description:** Phosphorylation at the proline-rich domain (T231, S235) by PKA/MAPK creates a \"phospho-epitope\" that nucleates further pathological phosphorylation and facilitates fibril nucleation. This modification precedes widespread phosphorylation and aggregation and is recognized by the AT180 antibody specifically in diseased tissue. Early intervention at this stage could prevent downstream aggregation cascade.\n\n**Target:** PKA; tau T231/S235 phosphorylation\n\n**Confidence:** 0.73\n\n---\n\n### Summary Table\n\n| Hypothesis | Target Modification | Therapeutic Approach | Confidence |\n|------------|---------------------|---------------------|------------|\n| 1 | K280 acetylation | SIRT1 activation, CBP inhibition | 0.78 |\n| 2 | D421 truncation | Caspase-3 inhibition | 0.82 |\n| 3 | S400/T403 O-GlcNAc loss | OGT activation | 0.71 |\n| 4 | N-terminal cleavage | Calpain inhibition | 0.69 |\n| 5 | Conformational epitope | Conformation-stabilizing agents | 0.75 |\n| 6 | Mitochondrial translocation |阻止Y18磷酸化 | 0.64 |\n| 7 | T231/S235 phosphorylation | Early-stage kinase inhibition | 0.73 |\n\n**Priority Targets:** Hypotheses 2 and 1 represent the highest confidence targets with established validation data. The caspase cleavage at D421 is particularly attractive as it creates a discrete molecular switch from functional to pathological tau.",
  "tokens_used": "1327"
}